September 30, 2011
Novartis AG of Switzerland announced on September 25 new data from the pivotal PIII IMPRES clinical trial showing that the tyrosine kinase inhibitor QT1571 (imatinib) significantly improved exercise capacity in patients with pulmonary arterial hypertension (PAH) after 24 weeks compared...read more